

1. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194–1210.
2. Denissenko MF, Pao A, Tang M, et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. *Science* 1996;274:430–432.
3. Wiencke JK, Thurston SW, Kelsey KT, et al. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. *J Natl Cancer Inst* 1999;91:614–619.
4. Phillips DH, Hewer A, Martin CN, et al. Correlation of DNA adduct levels in human lung with cigarette smoking. *Nature* 1988;336:790–792.
5. Landi MT, Chatterjee N, Yu K, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *Am J Hum Genet* 2009;85:679–691.
6. Truong T, Hung RJ, Amos CI, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. *J Natl Cancer Inst* 2010;102:959–971.
7. Sherva R, Wilhelmsen K, Pomerleau CS, et al. Association of a single nucleotide polymorphism in neuronal acetylcholine receptor subunit alpha 5 (CHRNA5) with smoking status and with 'pleasurable buzz' during early experimentation with smoking. *Addiction* 2008;103:1544–1552.
8. Lonardo F, Rusch V, Langenfeld J, et al. Overexpression of cyclin D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. *Cancer Res* 1999;59:2470–2476.
9. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. *Cancer Res* 2000;60:1949–1960.
10. Westra WH. Early glandular neoplasia of the lung. *Respir Res* 2000;1:163–169.
11. Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. *Cancer Res* 2003;63:1727–1730.
12. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer. *Oncogene* 2002;21:6877–6883.
13. Braithwaite KL, Rabbitts PH. Multi-step evolution of lung cancer. *Sem Cancer Biol* 1999;9:255–265.
14. Virmani AK, Gazdar AF. Tumor suppressor genes in lung cancer. *Methods Mol Biol* 2003;222:97–115.
15. Miura I, Graziano SL, Cheng JQ, et al. Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. *Cancer Res* 1992;52:1322–1328.
16. Testa JR, Siegfried JM. Chromosome abnormalities in human non-small cell lung cancer. *Cancer Res* 1992;52:2702s–2706s.
17. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 2007;131:1190–1203.
18. Haruki N, Kawaguchi KS, Eichenberger S, et al. Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro. *J Med Genet* 2005;42:558–564.
19. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561–566.
20. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. *Ann Rev Med* 2003;54:73–87.
21. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–525.
22. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. *Nature* 2013;502:333–339.
23. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069–1075.
24. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012;150:1107–1120.
25. Klein G, Klein E. Surveillance against tumors—is it mainly immunological? *Immunol Lett* 2005;100:29–33.
26. Sakumi K, Tomimaga Y, Furuichi M, et al. Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. *Cancer Res* 2003;63:902–905.
27. Zienoldiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. *Carcinogenesis* 2006;27:560–567.
28. Olausson KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. *N Engl J Med* 2006;355:983–991.
29. Friboulet L, Olausson KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. *N Engl J Med* 2013;368:1101–1110.
30. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. *N Engl J Med* 2007;356:800–808.
31. Bepko G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. *J Clin Oncol* 2006;24:4731–4737.
32. Kamal NS, Soria JC, Mendiboure J, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. *Clin Cancer Res* 2010;16:1206–1215.
33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129–2139.
34. Gao W, Lu X, Liu L, et al. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. *Cancer Biol Ther* 2012;13:330–340.
35. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004;101:13306–13311.
36. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. *J Clin Oncol* 2005;23:3227–3234.
37. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst* 2005;97:643–655.
38. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. *Cancer Res* 2005;65:1642–1646.
39. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. *N Engl J Med* 2005;353:133–144.
40. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). *Lancet* 2005;366:1527–1537.
41. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). *Br J Cancer* 2008;98:907–914.
42. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947–957.
43. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexid in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol* 2013;31:3327–3334.
44. Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. *Lancet Oncol* 2012;13:539–548.
45. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380–2388.
46. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010;11:121–128.
47. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011;12:735–742.
48. Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. *J Thorac Oncol* 2013;8:179–184.
49. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
50. Kobayashi S, Boggan TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2005;352:786–792.
51. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73.
52. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. *Nat Genet* 2005;37:1315–1316.
53. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. *J Clin Oncol* 2005;23:6838–6845.
54. Arcila ME, Chaff JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. *Clin Cancer Res* 2012;18:4910–4918.
55. Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. *J Thorac Oncol* 2010;5:1922–1932.
56. Tomizawa K, Suda K, Onozato R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. *Lung Cancer* 2011;74:139–144.
57. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol* 2004;15:19–27.
58. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. *Clin Lung Cancer* 2009;10:281–289.

59. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. *J Clin Oncol* 2013;31:1089–1096.
60. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2013;31:4105–4114.
61. Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. *J Clin Oncol* 2011;29:3307–3315.
62. Drilon A, Rekhtman N, Ladanyi M, et al. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. *Lancet Oncol* 2012;13:e418–e426.
63. Rooney M, Devarakonda S, Govindan R. Genomics of squamous cell lung cancer. *Oncologist* 2013;18:707–716.
64. Pollak MN. Insulin-like growth factors and neoplasia. *Novartis Found Symp* 2004;262:84–98.
65. Dziadziszko R, Merrick DT, Witta SE, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. *J Clin Oncol* 2010;28:2174–2180.
66. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med* 2010;2:62ra93.
67. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. *PLoS One* 2011;6:e20351.
68. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discov* 2011;1:78–89.
69. Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. *Eur J Pharmacol* 2008;599:44–53.
70. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res* 2008;14:4275–4283.
71. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693–1703.
72. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. *Cancer Res* 2008;68:4971–4976.
73. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. *Cancer* 2009;115:1723–1733.
74. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. *Mod Pathol* 2009;22:508–515.
75. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol* 2008;3:13–17.
76. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol* 2009;27:4247–4253.
77. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385–2394.
78. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res* 2012;18:1472–1482.
79. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci U S A* 2011;108:7535–7540.
80. Qi J, McTigue MA, Rogers A, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. *Cancer Res* 2011;71:1081–1091.
81. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734–1749.
82. Shaw AT, Mehra R, Kim D-W, et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. *J Clin Oncol* 2013;31:abstr 8010.
83. Nakagawa K, Kiura K, Nishio M, et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: updated safety and efficacy results from AF-001 JP. *J Clin Oncol* 2013;31:abstr 8033.
84. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. *Biochim Biophys Acta* 2009;1795:37–52.
85. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012;30:863–870.
86. Shaw AT, Camidge D, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. *J Clin Oncol* 2012;30:abstr 7508.
87. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. *Genome Res* 2012;22:436–445.
88. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat Med* 2012;18:375–377.
89. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med* 2012;18:378–381.
90. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov* 2013;3:630–635.
91. Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *J Clin Oncol* 2012;30:4352–4359.
92. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer* 2001;92:1525–1530.
93. Mascoux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *Br J Cancer* 2005;92:131–139.
94. Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. *J Clin Oncol* 2013;31:2173–2181.
95. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. *Cancer Discov* 2011;1:44–53.
96. Mok TSK, Paz-Ares L, Wu Y-L, et al. Association between tumor EGFR and KRAS mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the phase III MISSION trial [abstract]. *Ann Oncol* 2013;23:Abstract LBA9_PR.
97. Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncol* 2013;14:38–47.
98. Kelly K, Mazieres J, Leigh NB, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/II trial. *J Clin Oncol* 2013;31:abstr 8027.
99. Gandara DR, Hirt S, Blumenschein GR, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/II trial. *J Clin Oncol* 2013;31:abstr 8028.
100. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. *J Clin Oncol* 2011;29:2046–2051.
101. Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BR113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. *J Clin Oncol* 2013;31:abstr 8009.
102. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. *J Clin Oncol* 2013;31:e341–e344.
103. Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinomas. *J Clin Invest* 2014;124:1582–1586.
104. Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. *Cancer Res* 2008;68:5524–5528.
105. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304:554.
106. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. *Lung Cancer* 2006;54:209–215.
107. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519–525.
108. Chaff JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. *Mol Cancer Ther* 2012;11:485–491.
109. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc Natl Acad Sci U S A* 2005;102:802–807.
110. Zhang L, Shi L, Zhao X, et al. PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. *Oncotargets Ther* 2013;6:497–502.
111. Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. *Oncogene* 2008;27:5648–5650.
112. Carpen JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 2007;448:439–444.
113. Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. *Lung Cancer* 2010;69:279–283.
114. Tran B, Dancy JE, Kamel-Reid S, et al. Cancer genomics: technology, discovery, and translation. *J Clin Oncol* 2012;30:647–660.
115. Buettner R, Wolf J, Thomas RK. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. *J Clin Oncol* 2013;31:1858–1865.
116. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2010;2:146–158.
117. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. *PLoS One* 2009;4:e7887.
118. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol* 2011;22:2616–2624.
119. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). *J Clin Oncol* 2011;29:abstr CRA7506.

120. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. *Nature* 2011;475:348–352.
121. Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of bench-top high-throughput sequencing platforms. *Nat Biotechnol* 2012;30:434–439.
122. Chmielecki J, Rosenberg M, Imielinski M, et al. Whole exome and whole genome sequence analysis of lung adenocarcinoma. *Am Assoc Cancer Res* 2013;abstract 1112.
123. Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium. *Cancer Discov* 2013;3:1108–1112.
124. Macconail LE, Garraway LA. Clinical implications of the cancer genome. *J Clin Oncol* 2010;28:5219–5228.
125. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 2013;499:214–218.
126. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. *N Engl J Med* 2008;358:1118–1128.
127. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. *J Clin Oncol* 2013;31:4140–4147.
128. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. *Cancer Discov* 2011;1:598–607.
129. Chu BF, Karpenko MJ, Liu Z, et al. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. *Cancer Chemother Pharmacol* 2013;71:115–121.
130. Schrupp DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. *Clin Cancer Res* 2006;12:5777–5785.
131. Behrens C, Solis LM, Lin H, et al. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. *Clin Cancer Res* 2013;19:6566–6565.
132. Wagner KW, Alam H, Dhar SS, et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. *J Clin Invest* 2013;123:5231–5246.
133. Mitsudomi T, Oyama T, Kusano T, et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. *J Natl Cancer Inst* 1993;85:2018–2023.
134. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. *J Thorac Oncol* 2009;4:22–29.
135. Hwang SJ, Cheng LS, Lozano G, et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. *Hum Genet* 2003;113:238–243.
136. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. *Annu Rev Biochem* 2008;77:557–582.
137. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. *Cell* 2004;119:861–872.
138. Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. *Cell Cycle* 2010;9:472–478.
139. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. *Nat Cell Biol* 2007;9:573–580.
140. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. *Nature* 2007;450:893–898.
141. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. *Br J Cancer* 2004;91:1415–1419.
142. Eymin B, Cazzari S, Brambilla C, et al. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. *Oncogene* 2002;21:2750–2761.
143. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. *Nat Rev Cancer* 2009;9:724–737.
144. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. *Cell Cycle* 2007;6:1586–1593.
145. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. *Mol Cell* 2007;26:731–743.
146. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. *Curr Opin Oncol* 2008;20:90–96.
147. Rabinowitz G, Cercel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnostic marker for lung cancer. *Clin Lung Cancer* 2009;10:42–46.
148. Cazzoli R, Buttitta F, Di Nicola M, et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. *J Thorac Oncol* 2013;8:1156–1162.
149. Al-Nedawi K, Meehan B, Kerbel RS, et al. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. *Proc Natl Acad Sci U S A* 2009;106:3794–3799.
150. Aushev VN, Zborovskaya IB, Laktionov KK, et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. *PLoS One* 2013;8:e78649.
151. Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. *Clin Cancer Res* 2006;12:878–887.
152. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. *Nat Rev Cancer* 2011;11:726–734.
153. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. *Nature* 2007;450:893–898.
154. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. *Proc Natl Acad Sci U S A* 1998;95:11891–11896.
155. Zhang Y, Xiong Y, Yarbrough WC. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* 1998;92:725–734.
156. Meuwissen R, Linn SC, Linnoila RI, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. *Cancer Cell* 2003;4:181–189.
157. Beroukhi R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. *Nature* 2010;463:899–905.
158. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res* 2006;12:3209–3215.
159. Jansen M, Ten Klooster JP, Offerhaus GJ, et al. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. *Physiol Rev* 2009;89:777–798.
160. Carretero J, Medina PP, Pio R, et al. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. *Oncogene* 2004;23:4037–4040.
161. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. *Nature* 2007;448:807–810.
162. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. *Oncogene* 2007;26:5911–5918.
163. Amin RMS, Hiroshima K, Iyoda A, et al. LKB1 protein expression in neuroendocrine tumors of the lung. *Pathol Int* 2008;58:84–88.
164. Gwinn D, Shackelford D, Egan D, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. *Mol Cell* 2008;30:214–226.
165. Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. *Br J Cancer* 2009;100:370–375.
166. Robinson J, Lai C, Martin A, et al. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. *J Pathol* 2009;219:35–40.
167. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. *Cell Cycle* 2009;8:2031–2040.
168. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. *Diabetes Care* 2006;29:1990–1991.
169. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005;330:1304–1305.
170. Libby G, Donnelly L, Donnan P, et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. *Diabetes Care* 2009;32:1620–1625.
171. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. *J Clin Oncol* 2009;27:3297–3302.
172. Baas AF, Kuipers J, van der Wel NN, et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. *Cell* 2004;116:457–466.
173. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. *Nat Rev Cancer* 2009;9:563–575.
174. Baykara O, Demirkaya A, Kaynak K, et al. WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC). *Tumour Biol* 2010;31:315–320.
175. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069–1075.
176. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. *Oncogene* 2007;26:7283–7301.
177. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. *Cancer Res* 2000;60:6116–6133.
178. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily—CTLA-4. *Nature* 1987;328:267–270.
179. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol* 2012;30:2046–2054.
180. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol* 2013;24:75–83.
181. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–2454.
182. Brahmer J, Horn L, Antonia S, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase I trial. Abstract presented at: 2013 World Conference on Lung Cancer; 2013; Sydney, Australia.
183. Soria JC, Cruz C, Bahlleda R, et al. Clinical activity, safety, and biomarkers of PD-L1 blockade in non-small cell lung cancer; additional analyses from a clinical study of the engineered antibody MPDL2380A (Anti-PD-L1). Abstract presented at: 2013 European Cancer Congress; 2013; Amsterdam.

184. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. *Oncogene* 2002;21:4577–4586.
185. Zhu CQ, Cutz JC, Liu N, et al. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. *Br J Cancer* 2006;94:1452–1459.
186. Miura N, Nakamura H, Sato R, et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. *Cancer Sci* 2006;97:1366–1373.
187. Marchetti A, Pellegrini C, Buttitta F, et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. *Lab Invest* 2002;82:729–736.
188. Shibuya K, Fujisawa T, Hoshino H, et al. Increased telomerase activity and elevated hTERT mRNA expression during multistage carcinogenesis of squamous cell carcinoma of the lung. *Cancer* 2001;92:849–855.
189. Brunsvig PF, Kyte JA, Kersten C, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. *Clin Cancer Res* 2011;17:6847–6857.
190. Georgoulis V, Douillard JY, Khayat D, et al. A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. *Clin Lung Cancer* 2013;14:461–465.
191. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. *Oncogene* 2007;26:1324–1337.
192. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. *N Engl J Med* 1993;329:690–694.
193. Ikegaki N, Katsumata M, Minna J, et al. Expression of bcl-2 in small cell lung carcinoma cells. *Cancer Res* 1994;54:6–8.
194. Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. *Br J Cancer* 2003;89:55–64.
195. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. *Blood* 1993;81:3091–3096.
196. Mortenson MM, Schlieman MG, Virudachalam S, et al. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. *Lung Cancer* 2005;49:163–170.
197. Shivapurkar N, Reddy J, Matta H, et al. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. *Oncogene* 2002;21:8510–8514.
198. Park JY, Park JM, Jang JS, et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. *Hum Mol Genet* 2006;15:1963–1971.
199. Huang LN, Wang DS, Chen YQ, et al. Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies. *Mol Biol Rep* 2013;40:917–924.
200. Zhang LQ, Wang J, Jiang F, et al. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. *PLoS One* 2012;7:e34100.
201. Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. *Cancer Res* 2004;64:2840–2845.
202. Pore MM, Hiltermann TJ, Krutz FA. Targeting apoptosis pathways in lung cancer. *Cancer Lett* 2013;332:359–368.
203. Ambros V. The functions of animal microRNAs. *Nature* 2004;431:350–355.
204. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. *Science* 2001;294:853–858.
205. Croce CM. Causes and consequences of microRNA dysregulation in cancer. *Nat Rev Genet* 2009;10:704–714.
206. Calin GA, Cimmino A, Fabbri M, et al. miR-15a and miR-16-1 cluster functions in human leukemia. *Proc Natl Acad Sci U S A* 2008;105:5166–5171.
207. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. *Nat Genet* 2006;38:1060–1065.
208. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer* 2006;6:857–866.
209. Bommer GT, Cerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. *Curr Biol* 2007;17:1298–1307.
210. Izzotti A, Calin GA, Arrigo P, et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. *FASEB J* 2009;23:806–812.
211. Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. *Nature* 2004;432:235–240.
212. Han J, Lee Y, Yeom KH, et al. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev* 2004;18:3016–3027.
213. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. *RNA* 2004;10:185–191.
214. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. *Cancer Sci* 2005;96:111–115.
215. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell* 2006;9:189–198.
216. Lu Y, Govindan R, Wang L, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. *Carcinogenesis* 2012;33:1046–1054.
217. Nadal E, Chen G, Gallegos M, et al. Epigenetic inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma. *Clin Cancer Res* 2013;19:6842–6852.
218. Akagi I, Okayama H, Schetter AJ, et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. *Cancer Res* 2013;73:3821–3832.
219. Keller A, Backes C, Leidinger P, et al. Next-generation sequencing identifies novel microRNAs in peripheral blood of lung cancer patients. *Mol Biosyst* 2011;7:3187–3199.
220. Dacic S, Kelly L, Shuai Y, et al. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. *Mod Pathol* 2010;23:1577–1582.
221. Garofalo M, Romano G, Di Leva G, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. *Nat Med* 2010;16:74–82.
222. Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. *Ann Oncol* 2008;19:1053–1059.
223. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. *J Biol Chem* 2009;284:5731–5741.
224. Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. *RNA Biol* 2011;8:125–131.
225. Chou YT, Lin HH, Lien YC, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. *Cancer Res* 2010;70:8822–8831.
226. Rai K, Takigawa N, Ito S, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. *Mol Cancer Ther* 2011;10:1720–1727.
227. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. *N Engl J Med* 2013;368:1685–1694.
228. Mirna Therapeutics, Inc. A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension. Clinical Trials.gov Web site. <http://clinicaltrials.gov/ct2/show/NCT01829971>.
229. Schembri F, Sridhar S, Perdomo C, et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. *Proc Natl Acad Sci U S A* 2009;106:2319–2324.
230. Davidson MR, Larsen JE, Yang IA, et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. *PLoS One* 2010;5:e12560.
231. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. *BMC Cancer* 2011;11:374.
232. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. *Proc Natl Acad Sci U S A* 2011;108:3713–3718.
233. Lei L, Huang Y, Gong W. miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEEN. *Oncol Rep* 2013;30:2897–2902.
234. Romano G, Acunzo M, Garofalo M, et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. *Proc Natl Acad Sci U S A* 2012;109:16570–16575.
235. Shen J, Liao J, Guarnera MA, et al. Analysis of microRNAs in sputum to improve computed tomography for lung cancer diagnosis. *J Thorac Oncol* 2014;9:33–40.
236. Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. *Mod Pathol* 2010;23:1157–1164.
237. Kosaka N, Iguchi H, Yoshioka Y, et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J Biol Chem* 2010;285:17442–17452.
238. Turchinovich A, Weiz L, Langhein A, et al. Characterization of extracellular circulating microRNA. *Nucleic Acids Res* 2011;39:7223–7233.
239. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. *Semin Oncol* 2005;32:315–328.
240. Acuff HB, Sinnamon M, Fingleton B, et al. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. *Cancer Res* 2006;66:7968–7975.
241. Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. *Genes Dev* 2009;23:2140–2151.
242. Sandler AB. Targeting angiogenesis in lung cancer. *Semin Oncol* 2005;32: S16–S22.
243. Mineo TC, Ambrogio V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. *J Clin Pathol* 2004;57:591–597.
244. Reck M, von Pawel J, Zatlokal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol* 2009;27:1227–1234.
245. Reck M, von Pawel J, Zatlokal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAIL). *Ann Oncol* 2010;21:1804–1809.

246. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542–2550.
247. Jordan CT, Guzman ML, Noble M. Cancer stem cells. *N Engl J Med* 2006;355:1253–1261.
248. Germano D, Blyszczek P, Valaperti A, et al. Prominin-1/CD133+ lung epithelial progenitors protect from bleomycin-induced pulmonary fibrosis. *Am J Respir Crit Care Med* 2009;179:939–949.
249. Kim CFB, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. *Cell* 2005;121:823–835.
250. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. *Proc Natl Acad Sci U S A* 2009;106:16281–16286.
251. Chen Y-C, Hsu H-S, Chen Y-W, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. *PLoS One* 2008;3:e2637.
252. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. *Cell Death Differ* 2008;15:504–514.
253. Jiang T, Collins BJ, Jin N, et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. *Cancer Res* 2009;69:845–854.
254. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. *Mol Cancer Res* 2009;7:330–338.
255. Pine SR, Ryan BM, Varticovski L, et al. Microenvironmental modulation of asymmetric cell division in human lung cancer cells. *Proc Natl Acad Sci U S A* 2010;107:2195–2200.
256. Jaksch M, Múnera J, Bajpai R, et al. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. *Cancer Res* 2008;68:7882–7886.
257. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133– metastatic colon cancer cells initiate tumors. *J Clin Invest* 2008;118:2111–2120.
258. Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. *Science* 2007;317:337.
259. Sullivan JP, Spinola M, Dodge M, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. *Cancer Res* 2010;70:9937–9948.
260. Giacalone NJ, Den RB, Eisenberg R, et al. ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. *Future Oncol* 2013;9:737–745.
261. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature* 2006;439:353–357.
262. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.